亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北恒碩化工科技有限公司  

泊洛沙姆、尼美舒利、氯氮平、尼可地爾、醋酸洗泌泰、α,β,γ環糊精、多潘立酮、正丁基硫代磷酰三胺

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:徐文琪
  • 電話:027-82832071
  • 郵件:1461023922@qq.com
  • 傳真:027-82830253
  • QQ:1461023922
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 奧美沙坦酯
奧美沙坦酯
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后24小時內
庫存 10000公斤起訂1公斤
品牌 恒碩
過期 長期有效
更新 2019-03-27 15:51
 
詳細信息
 奧美沙坦酯

中文別名: 2,3-二羥基-2-丁烯基-4-(1-羥基-1-甲基乙基)-2-丙基-1-[4-(2-1H-四唑-5-苯基)芐基]咪唑-5-羧酸酯環-2,3-碳酸酯。         

英文名稱: olmesartan medoxomil         

CAS  號: 144689-63-4;144689-78-1        

式: C29H30N6O6        分子量:558.59        

物化性質: 白色或類白色粉末。   熔點 180℃          

產品用途: 抗高血壓藥。         

包裝規格: 25KG/紙板桶包裝,內襯聚乙烯袋。可按客戶要求包裝。       

關鍵字詞:奧美沙坦酯的價格;奧美沙坦酯多少錢;奧美沙坦酯原料藥;奧美沙坦酯的生產廠家;奧美沙坦酯的生產商;奧美沙坦酯的制造商;奧美沙坦酯的生產企業;奧美沙坦酯的介紹 說明書;奧美沙坦酯的成分;奧美沙坦酯的作用 用途。

©2025 湖北恒碩化工科技有限公司 版權所有   技術支持:化工網   訪問量:35483  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |